Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction

BACKGROUND: Angiotensin receptor neprilysin inhibitor (ARNi) therapy improves clinical outcomes in patients with heart failure and reduced left ventricular ejection fraction. However, ARNi therapy uptake remains modest, potentially in part due to perceived cost considerations of early transition fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Grant, Andrew D.M., Chew, Derek S., Howlett, Jonathan G., Miller, Robert J.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710928/
https://www.ncbi.nlm.nih.gov/pubmed/33305203
http://dx.doi.org/10.1016/j.cjco.2020.05.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710928/
https://www.ncbi.nlm.nih.gov/pubmed/33305203
http://dx.doi.org/10.1016/j.cjco.2020.05.009

Ejemplares similares